Original Article

Delineation of biological and molecular mechanisms underlying the diverse anticancer activities of mycophenolic acid

Boying Dun1,2,3, Heng Xu2,3, Ashok Sharma2, Haitao Liu2, Hongfang Yu2, Bing Yi2, Xiaoxin Liu3, Mingfang He3, Lingwen Zeng1, Jin-Xiong She2,3

1Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Road, Guangzhou 510530, China; 2Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Georgia Regents University, 1120 15th Street, Augusta, GA 30912, USA; 3Institute of Translational Medicine, School of Pharmaceutical Sciences, Nanjing University of Technology, Nanjing, China

Received October 1, 2013; Accepted October 30, 2013; Epub November 15, 2013; Published December 1, 2013

Abstract: Background: Mycophenolate mofetil (MMF), the prodrug of mycophenolic acid (MPA) which has been widely used for the prevention of acute graft rejection, is a potent inhibitor of inosine monophosphate dehydrogenase (IMPDH) that is up-regulated in many tumors and potentially a target for cancer therapy. MPA is known to inhibit cancer cell proliferation and induces apoptosis; however, the underlying molecular mechanisms remain elusive. Methods: We first demonstrated MPA's antiproliferative and proapoptotic activities using in vitro studies of 13 cancer cell lines and a xenograft model. Key proteins involved in cell cycle, proliferation and apoptosis were analyzed by Western blotting. Results: In vitro treatment of thirteen cancer cell lines indicated that five cell lines (AGS, NCI-N87, HCT-8, A2780 and BxPC-3) are highly sensitive to MPA (IC50 < 0.5 µg/ml), four cell lines (Hs746T, PANC-1, HepG2 and MCF-7) are very resistant to MPA (IC50 > 20 µg/ml) and the four other cell lines (KATO III, SNU-1, K562 and HeLa) have intermediate sensitivity. The anticancer activity of MPA was confirmed in vivo using xenograft model with gastric AGS cell line. Further in vitro analyses using AGS cells indicated that MPA can potently induce cell cycle arrest and apoptosis as well as inhibition of cell proliferation. Targeted proteomic analyses indicate that many critical changes responsible for MPA's activities occur at the protein expression and phosphorylation levels. MPA-induced cell cycle arrest is achieved through reduction of many cell cycle regulators such as CDK4, BUB1, BOP1, Aurora A and FOXM1. We also demonstrate that MPA can inhibit the PI3K/AKT/mTOR pathway and can induce caspase-dependent apoptosis. Conclusions: These results suggest that MPA has beneficial activities for anticancer therapy through diverse molecular pathways and biological processes.

Keywords: MPA, drug repurposing, cancer, apoptosis, xenograft

Introduction

Mycophenolate mofetil (MMF) is approved for the prevention of acute graft rejection in transplantation [1, 2]. MMF is the morpholinoethyl ester prodrug of mycophenolic acid (MPA), which is a potent uncompetitive inhibitor of inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme for the de novo synthesis of guanosine nucleotides [3, 4], which play crucial roles in cell proliferation and other cellular functions [5]. Consequently, MPA blocks T and B lymphocyte proliferation and clonal expansion, and prevents the generation of cytotoxic T cells and other effector T cells. Other mechanisms may also contribute to the efficacy of MPA in preventing allograft rejection. Through depletion of guanosine nucleotides, MPA can suppress glycosylation and the expression of several adhesion molecules, thereby decreasing the recruitment of lymphocytes and monocytes into sites of inflammation and graft rejection [4]. It has recently been shown that IMPDH can function as a sequence-specific DNA-binding transcription factor [6]. Although IMPDH is largely cytoplasmic, IMPDH can accumulate in the nucleus, where it binds and represses histone genes and E2F, the master driver of the G1/S transition.
The expression of IMPDH, particularly IMPDH2, is significantly up-regulated in many tumor cells [7, 8]. Therefore, IMPDH is potentially a target for cancer therapy in addition to immunosuppressive chemotherapy. MPA/MMF has been reported to inhibit cancer cell proliferation and induces apoptosis in vitro and in vivo, such as multiple myeloma cells [9], HL-60 cells [10], lymphoma [11], Walker’s carcinosarcoma [12], U87 glioblastoma cells [13], pancreatic, lung and colon cancer [14]. However, the precise signaling pathways underlying MPA’s activities remain elusive. The reported mechanisms include its ability to induce and activate p53 [15], a key tumor suppressor molecule involved in cell cycle control and apoptosis and its ability to inhibit the surface expression of some integrins [16].

To gain further insights into the biological and molecular mechanisms of MPA, we investigated the anticancer activity of MPA in multiple cancer cell lines and the molecular changes after MPA treatment using targeted proteomic analyses.

**Materials and methods**

**Cell viability and proliferation assays**

Cell viability was assayed using a cell counting kit-8 (CCK-8) from Dijindo Molecular Technologies (Rockville, Maryland). Approximately 3500 cells were seeded into 96 well plate 24 h before MPA treatment. An equal volume (1 µl) of different concentration of MPA (0.4 µg/ml - 2 mg/ml) was added to each well. After incubation for 24, 48 or 72 hours, culture medium was removed and replaced by 100 µl of fresh medium containing 5 µl CCK-8. After 4 h incubation, OD values were measured at 450 nm using the multi-functional microplate reader.

**In vivo experiments**

This study was approved by the Georgia Regents University IACUC committee. About 2 x 10⁶ AGS cells (per mouse) in 100 µl PBS with matrigel (Sigma) (1 : 1) were inoculated subcutaneously in the right leg flank of male Balb/c nude mice (4-6 weeks of age). Two weeks post-inoculation, when the tumor sizes reached approximately 100 mm³, mice were randomly divided into two groups. For the MPA treated group, mice were injected intraperitoneally with MPA (2 mg/mouse) once daily. For the control group, mice were treated with vehicle. The weights of mice were similar within each treatment group. Tumor volumes and body weight were measured once every three days.

**Western blotting**

Cells were harvested and resuspended in PBS. After centrifugation at 2000 rpm for 5 min, the pellet was lysed in ice cold M-PER Mammalian Protein Extraction Reagent containing 1% Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific) for 30 min. The supernatant was collected after 10 min of centrifugation at 12000 rpm, equaled by spectrophotometry, denatured with sample loading buffer for 10 min at 95°C and stored at 4°C for future use. Proteins were separated by 10% SDS-polyacrylamide gels and transferred to PVDF membrane, and incubated with primary antibodies of interest at 4°C overnight. The appropriate horseradish-conjugated secondary antibody at a dilution of 1 : 10000 in blocking buffer (3% BSA-TBST) was added and incubated for 1 h at room temperature. All antibodies were diluted in 3% BSA-TBST. Antibodies were purchased from Abcam (BOP1; Santa Cruz for GAPDH, p53, PI3-Kinase beta85), Cell Signaling (caspase 3, cleaved caspase 3, caspase 9, cleaved caspase 9, caspase 7, cleaved caspase 7, caspase 8, cleaved caspase 8, PARP, Bcl2, Bcl-xl, BUB1b, Aurora A, PI3K p110a, Akt, p-Akt (Ser473), p-p70S6 Kinase (Thr389)) and BD biosciences (AIF).

**Results**

**MPA has potent in vitro anticancer activity**

Thirteen cancer cell lines were treated with serial dilutions of MPA (0.04 - 20 µg/ml) for 72 hours to evaluate MPA’s activity on cell proliferation (Figure 1A, 1B). Five cell lines (AGS, NCI-N87, HCT-8, A2780 and B x PC-3) are highly sensitive to MPA (IC₅₀ < 0.5 µg/ml), four cell lines (Hs746T, PANC-1, HepG2 and MCF-7) are very resistant to MPA (IC₅₀ > 20 µg/ml) and the four other cell lines (KATO III, SNU-1, K562 and HeLa) have intermediate sensitivity. As the gastric cancer cell line, AGS, is one of the most sensitive cell lines which can establish xenograft tumors in mice in our lab, it was selected for the subsequent studies.

**MPA inhibits cancer growth in vivo**

Based on the in vitro results, we evaluated the in vivo anti-tumor activity of MPA using the
Molecular mechanism of MPA's anticancer activity

As shown in Figure 2A, MPA significantly inhibited tumor growth in the first three weeks and completely halted tumor growth afterwards by MPA treatment ($p = 5.5 \times 10^{-5}$). Tumors were weighted after 30 days of MPA treatment and the average tumor weight was significantly lower in the treated group compared to vehicle control group ($p = 6.2 \times 10^{-4}$, Figure 2B, 2C).

**MPA induces cell cycle arrest**

AGS cells at different time points of MPA treatment were stained with Propidium Iodide (PI)
and analyzed by flow cytometry. As shown in Figure 3A, 3B, MPA treatment increased the percentages of cells in the G0/G1 phase starting at 12 h and in a time-dependent manner, suggesting that MPA treatment induces cell cycle arrest. The FACS data also indicated that MPA treatment significantly increased the percentage of apoptotic cells starting at the 24 h time point and in a time-dependent manner (Figure 3C). Treatment of AGS cells with MPA caused obvious morphological changes such as chromatin condensation and nuclear fragmentations as revealed by Hoechst staining (Figure 3D).

The tumor suppressor protein p53 mediates cell cycle G1 phase arrest in response to a variety of stress stimuli. We confirmed by Western blot analysis that p53 protein expression is significantly increased after MPA treatment (Figure 4A). Several kinases implicated in cell cycle control are also significantly altered by MPA treatment. Western blot analysis revealed a dramatic reduction of the CDK4 and BUB1 protein after MPA treatment (Figure 4A). BUB1 and BUB1B are two related mitotic checkpoint serine/threonine-protein kinases, which are involved in spindle checkpoint function. Many cancers have impaired spindle checkpoint function. The Aurora A and Aurora B kinases play important roles in mitosis. Aurora A kinase regulates spindle assembly and stability, while Aurora B kinase regulates chromosome segregation and cytokinesis. The Aurora A protein (Figure 4A) was significantly down-regulated by MPA treatment.
Molecular mechanism of MPA's anticancer activity

FOXM1 is known to play a key role in cell cycle progression. Endogenous FOXM1 expression peaks at S and G2/M phases [17]. FOXM1 knockout mice are neonatal lethal as a result of the development of polyploid cardiomyocytes and hepatocytes, highlighting the role of FOXM1 in mitotic division. FOXM1 regulates expression of a large array of G2/M-specific genes. It plays an important role in maintaining chromosomal segregation and genomic stability [18]. The FOXM1 protein is severely down-regulated (Figure 4A) by MPA treatment.

BOP1 is a ribosome biogenesis protein involved in rRNA processing, thereby controlling the cell cycle [19]. It is required for the maturation of the 25 S and 5.8 S ribosomal RNAs and it may serve as an essential factor in ribosome formation. The BOP1 complex is involved in ribosome biogenesis and altered chromosome segregation. The expression of BOP1 protein (Figure 4A) is significantly reduced by MPA treatment.

MPA inhibits cell proliferation via the PI3K-AKT-mTOR pathway

The PI3K-AKT-mTOR pathway, which is activated by receptor tyrosine kinases (RTK), plays a critical role in cell proliferation. Western blot analyses revealed that MPA treatment slightly decreased PI3K p85beta protein expression but drastically decreased phosphorylated PI3K p110a in a time-dependent manner (Figure 4B). The total AKT protein only showed slight change at later time points; however, phospho-Akt (Ser473) was severely decreased by MPA treatment (Figure 4B). Furthermore, the phospho-p70S6 kinase (Thr389), an mTOR component, was also dramatically down-regulated by MPA treatment. These results suggest that inhibition of the PI3K/AKT/mTOR pathway is a major mechanism through which MPA inhibits AGS cell proliferation. In many cancers, the PI3K/AKT/mTOR pathway is over-active, allowing proliferation of cancer cells [20-22]. A number of experimental anti-cancer drugs aim to inhibit this signaling pathway. Our results suggest that MPA treatment results in, most likely through an indirect mechanism, effective inhibition of the PI3K/AKT/mTOR pathway.

MPA induces caspase-dependent apoptosis

Next, we attempted to elucidate the apoptotic pathways induced by MPA treatment using Western blotting technique. Caspases are proteolytic enzymes that play critical roles in apoptosis. Caspase 8 can self-activate through proteolytic cleavage upon binding with FADD. Active caspase 8 is then released into the cytosol, where it cleaves other effector caspases, eventually leading to DNA degradation, membrane blebbing, and other hallmarks of apoptosis. Caspase 8 is highly activated in AGS cells after MPA treatment (Figure 4C), suggesting that the Fas-mediated apoptosis pathway is activated by MPA treatment. The mitochondrial apoptosis pathway is also activated by MPA treatment as indicated by the activation of another initiator caspase, caspase 9 (Figure 4C). As expected, two effector caspases, caspase 3 and caspase
Molecular mechanism of MPA's anticancer activity

7, are also highly activated in MPA-treated AGS cells. Poly (ADP-ribose) polymerase (PARP) is activated by caspase cleavage (Figure 4C). Activation of PARP expedites cellular disassembly by rapid catalysis of NAD$^+$ and subsequent ATP depletion. It is also a robust indicator of cells undergoing apoptosis. These proteins are significantly altered after 24 h treatment time point, which is consistent with the apoptotic phenotype observed starting at the 24 h time point (Figure 3B). However, MPA treatment did not alter the protein expression of two anti-apoptotic members of the Bcl family (namely Bcl-2 and Bcl-xL) (Figure 4C).

There also exists a caspase-independent apoptotic pathway that is mediated by apoptosis-inducing factor (AIF) [23]. In our experiments, the expression of AIF was not altered by MPA treatment (Figure 4C), suggesting that the caspase-independent apoptosis pathway is not activated by MPA treatment.

Discussion

Our extensive functional studies indicate that MPA can exert potent antitumor activities including cell cycle arrest, inhibition of proliferation, and induction of apoptosis. MPA can inhibit cell proliferation in 9 of the 13 cell lines. Consistent with MPA’s in vitro functions, our study also demonstrated the in vivo anticancer activity of MPA in mice bearing AGS xenografts.

Although the anticancer activities of MPA are now well established, it is still unclear how this drug exerts its functions. In this study, we used proteomic and functional technologies to elucidate the molecular and biological pathways activated or inhibited by MPA. Our targeted proteomic studies allowed us to identify several key signaling pathways involved in the MPA regulatory network. For example, the phosphorylated PI3K, AKT and mTOR were dramatically reduced by MPA treatment.

MPA-induced cell cycle arrest already occurred at the 12 h time point, while alterations in cell proliferation and apoptosis only became apparent at the 24 h time point (Figure 3B). At the proteomic level, many key proteins involved in cell cycle arrest are also significantly altered at the 12 h time points (Figure 4A), while the proteins involved in proliferation (Figure 4B) and especially those involved in apoptosis are only altered at the 24 h and later time points. Therefore, both functional and molecular data suggest that arresting cell cycle may be the first and most important mechanism underlying MPA’s anticancer activity.

One of the main consequences of MPA treatment is the reduced expression or phosphorylation of a number of kinases such as PI3K, AKT and PKC that are key signaling nodes known to be implicated in multiple cellular functions including cell cycle, proliferation and apoptosis. Consistent with a previous report [15], p53, a key tumor suppressor molecule involved in cell cycle control and apoptosis, is up-regulated by MPA. Furthermore, a number of kinases involved in cell cycle regulation such as BUB1, BUB1B, AURKA, AURKB and BOP are drastically reduced by MPA. The changes in these key node proteins can account for the expression changes of a large number of downstream effector molecules implicated in the observed biological functions. Our functional and molecular data suggest that the FDA-approved immunosuppressive drug MMF may be a good candidate that may be repurposed for anticancer therapy in certain human cancer patients.

Acknowledgements

JXS is partially supported by the Georgia Research Alliance as an eminent scholar.

Disclosure of conflict of interest

The authors have declared that no competing interests exist.

Address correspondence to: Dr. Jin-Xiong She, Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Georgia Regents University, 1120 15th Street, Augusta, 30912, USA. Tel: 706-721-3410; Fax: 706-721-3688; E-mail: jshe@gru.edu

References


Molecular mechanism of MPA’s anticancer activity


